164 related articles for article (PubMed ID: 37145126)
1. Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action.
Elmetwalli A; Diab T; Albalawi AN; El-Naggar SA; El-Far AH; Ghedan AR; Alamri ES; Salama AF
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2501-2517. PubMed ID: 37145126
[TBL] [Abstract][Full Text] [Related]
2. Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage.
Attia AA; Salama AF; Eldiasty JG; Mosallam SAE; El-Naggar SA; El-Magd MA; Nasser HM; Elmetwalli A
Sci Rep; 2022 Apr; 12(1):6494. PubMed ID: 35444229
[TBL] [Abstract][Full Text] [Related]
3. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
5. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
[TBL] [Abstract][Full Text] [Related]
6. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
[TBL] [Abstract][Full Text] [Related]
7. Gingerol and/or sorafenib attenuates the DAB-induced HCC and hepatic portal vein dilatation via ATG4/CASP3 and COIIV/COX-2/NF-κB expression.
Salama AF; El-Far AH; Anbar EA; El-Naggar SA; Elshazli RM; Elmetwalli A
Med Oncol; 2024 Jan; 41(2):57. PubMed ID: 38228916
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex.
Phan C; Zheng Z; Wang J; Wang Q; Hu X; Tang G; Bai H
Biomater Sci; 2019 Nov; 7(11):4758-4768. PubMed ID: 31509117
[TBL] [Abstract][Full Text] [Related]
9. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
[TBL] [Abstract][Full Text] [Related]
10. The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach.
Hosseinzadeh F; Ai J; Hajifathali A; Muhammadnejad S; Ebrahimi-Barough S; Seyhoun I; Komeili Movahed T; Shirian S; Hosseinzadeh F; Ahmadpour S; Alijani M; Verdi J
Pharmacol Rep; 2022 Apr; 74(2):379-391. PubMed ID: 35089543
[TBL] [Abstract][Full Text] [Related]
11. Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines.
Abdel Wahab AHA; Ayad EG; Abdulla MS; Sharada HM; Ashmawy AM
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2951-2958. PubMed ID: 34582667
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk.
Habiba YH; Omran GA; Helmy MW; Houssen ME
Life Sci; 2022 May; 297():120443. PubMed ID: 35245519
[TBL] [Abstract][Full Text] [Related]
13. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
Wild AT; Gandhi N; Chettiar ST; Aziz K; Gajula RP; Williams RD; Kumar R; Taparra K; Zeng J; Cades JA; Velarde E; Menon S; Geschwind JF; Cosgrove D; Pawlik TM; Maitra A; Wong J; Hales RK; Torbenson MS; Herman JM; Tran PT
PLoS One; 2013; 8(6):e65726. PubMed ID: 23762417
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the oxidative damage, inflammation, and apoptosis-related genes by dicinnamoyl-L-tartaric acid in liver cancer.
Elmetwalli A; Hashish SM; Hassan MG; El-Magd MA; El-Naggar SA; Tolba AM; Salama AF
Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3087-3099. PubMed ID: 37160480
[TBL] [Abstract][Full Text] [Related]
15. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
Romito I; Porru M; Braghini MR; Pompili L; Panera N; Crudele A; Gnani D; De Stefanis C; Scarsella M; Pomella S; Levi Mortera S; de Billy E; Conti AL; Marzano V; Putignani L; Vinciguerra M; Balsano C; Pastore A; Rota R; Tartaglia M; Leonetti C; Alisi A
J Exp Clin Cancer Res; 2021 Nov; 40(1):364. PubMed ID: 34784956
[TBL] [Abstract][Full Text] [Related]
16. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
17. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
18. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
19. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
Ma D; Wang J; Liu L; Chen M; Wang Z
BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
